Dr Sanil Rege

November 24, 2022

Time to read: 33–40 minutes

Humans spend 1/3rd of their life sleeping. Sleep is critical to adaptive human functioning with its links to cognition, mood, ...

 Dr Sanil Rege

October 27, 2022

Time to read: 10 minutes

Memantine is a low-affinity voltage-dependent non-competitive NMDA receptor antagonist that is approved for treating moderate-...

 Dr Sanil Rege

September 30, 2022

Time to read: 16–19 minutes

The interaction between smoking and schizophrenia is complex and multifaceted, with patients consistently showing higher rates...

In this video, Dr Sanil Rege reviews the ...

In this video, Dr Sanil Rege explores the use of network meta-analysis to make indirect comparisons between drugs that have not been compared in head-to...

 Dr Sanil Rege

July 25, 2022

Time to read: 17–20 minutes

When patients with Major Depressive Disorder (MDD) don’t respond to medication, clinicians have three options: Increase dose, switch or augment....

In this video, Dr Sanil Rege, Consultant Psychiatrist and Academic Lead of Psych Scene talks to Prof Ian Hickie and A/Prof Liz...

In this video Dr Sanil Rege, Consultant Psychiatrist covers the mechanism of action of Agomelatine. Agomelatine has recently been TGA approved fo...

Long-acting injectable antipsychotics (LAIs) are an effective treatment option in schizophrenia.  However, they are often viewed negatively by clinicia...

 Dr Sanil Rege

June 17, 2022

Time to read: 11–13 minutes

Brexpiprazole (Rexulti) is a partial dopamine (D2) agonist. Brexpiprazole [7-{4-[4-(1-benzothiophene-4-yl) piperazin-1-yl]butoxy}quinolin-2(1H)-o...